|
TZ-48 Molecular Probe for Early Alzheimer’s Detection
Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) develop a molecular probe, TZ-48, for early-stage detection of Alzheimer’s Disease (AD).
TZ-48 Molecular Probe and ADxFluor:
| Dimension | Key Details |
|---|---|
| Probe type | TZ-48 comprises a fluorescence lifetime-responsive molecular probe. |
| Target binding | TZ-48 selectively binds to misfolded Amyloid-β (Aβ) fibrils. |
| Fluorescence response | TZ-48 produces a turn-on fluorescence response and distinct lifetime signatures. |
| Associated tool | ADxFluor uses a dedicated smartphone application to capture and quantify changes in fluorescence intensity. |
| Testing mode | ADxFluor enables rapid, objective, and point-of-care biofluid testing. |
| Blood-Brain Barrier | TZ-48 exhibits high Blood-Brain Barrier (BBB) permeability. |
| Animal model evidence | TZ-48 demonstrates robust labeling of Aβ plaques in animal models. |
| Utility coverage | TZ-48 demonstrates utility in brain tissue imaging and biofluid detection in blood serum and cerebrospinal fluid. |
| Cost comparison | The technology provides a low-cost alternative to diagnostic tools such as Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), and complex laboratory-bound immunoassays. |
| Alzheimer’s disease description | Alzheimer’s Disease comprises a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and behavioral changes. |
| Role of Amyloid-β (Aβ) | Alzheimer’s Disease is caused by the misfolding and aggregation of Aβ peptides into extracellular amyloid plaques, which trigger neurotoxic cascades, synaptic dysfunction, and neuronal cell death. |
| Biomarker significance | Aβ pathology is recognized as an early and highly specific hallmark biomarker, essential for timely intervention before irreversible cognitive damage occurs. |